NCT05112705 Diagnosing Deep-vein Thrombosis Early in Critically Ill Patients
| NCT ID | NCT05112705 |
| Status | Recruiting |
| Phase | — |
| Sponsor | King Abdullah International Medical Research Center |
| Condition | Deep Vein Thrombosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,800 participants |
| Start Date | 2023-03-21 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,800 participants in total. It began in 2023-03-21 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The DETECT randomized controlled trial addresses the question of whether surveillance ultrasound in critically ill patients by facilitating DVT detection reduces the incidence of PE and lowers all-cause 90-day mortality. The primary outcome is 90-day all-cause mortality.
Eligibility Criteria
Inclusion criteria 1. Medical, surgical or trauma ICU patients ≥18 years old. 2. Patients who are expected to stay in the ICU more than 2 calendar days (unlikely to be discharged out of ICU on the day of admission or on the next day). Exclusion Criteria 1. Patients with DVT or PE diagnosed within the last year. 2. Patients receiving chronic systemic anticoagulation. 3. Patients who have received up to the time of ICU admission or are receiving therapeutic doses of anticoagulation with UFH, LMWH, or other anticoagulants. 4. Inability or contraindication to obtain adequate ultrasound on the lower extremities (Burns in the lower extremities, lacerations, active skin infection, \& ischemic limb in the legs, large dressings in the thighs that prevent adequate ultrasounds OR amputated foot or leg on one or two sides) 5. Patients with Inferior Vena Cava (IVC) Filter. 6. Known or suspected pregnancy. 7. Limitation of life support, life expectancy \<7 days or palliative care. 8. Previously enrolled in DETECT trial within the last 180 days. 9. Enrolled in another trial for which co-enrolment is not approved.
Contact & Investigator
Yaseen M Arabi
PRINCIPAL INVESTIGATOR
King Saud bin Abdulaziz University of Health Sciences
Frequently Asked Questions
Who can join the NCT05112705 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Deep Vein Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05112705 currently recruiting?
Yes, NCT05112705 is actively recruiting participants. Contact the research team at yaseenarabi@yahoo.com for enrollment information.
Where is the NCT05112705 trial being conducted?
This trial is being conducted at Riyadh, Saudi Arabia.
Who is sponsoring the NCT05112705 clinical trial?
NCT05112705 is sponsored by King Abdullah International Medical Research Center. The principal investigator is Yaseen M Arabi at King Saud bin Abdulaziz University of Health Sciences. The trial plans to enroll 1,800 participants.